Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Cognition Therapeutics

CGON

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Cognition Therapeutics. A complete text table follows the diagram.

Cognition Therapeutics Pipeline Flow

A clinical-stage therapeutics platform is supported by limited collaboration revenue.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001193125-26-214669
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Cognition reports $1.083M of license and collaboration revenue and no supported product-sales allocation. The flow therefore shows only reported revenue and leaves the development pipeline qualitative.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Cognition Therapeutics revenue	1	$1.1M	$1.083M reported quarterly revenue
License and collaboration revenue	2	$1.1M	Reported license and collaboration revenue

Financial flows · Millions of USD
From	To	Value
Cognition Therapeutics revenue	License and collaboration revenue	$1.1M